» Articles » PMID: 39041606

Are Community Oncology Practices with or Without Clinical Research Programs Different? A Comparison of Patient and Practice Characteristics

Overview
Specialty Oncology
Date 2024 Jul 23
PMID 39041606
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Expanding access to clinical trials in community settings is a potential approach to addressing disparities in accrual of historically underrepresented populations. However, little is known about the characteristics of practices that do not participate in research. We investigated differences in patient and practice characteristics of US community oncology practices with high vs low engagement in clinical research.

Methods: We included patients from a real-world, nationwide electronic health record-derived, de-identified database who received active treatment for cancer at community oncology practices between November 1, 2017, and October 31, 2022. We assessed patient and practice characteristics and their associations with high vs low research engagement using descriptive analyses and logistic regression models.

Results: Of the 178 practices, 70 (39.3%) events had high research engagement, treated 57.8% of the overall 568 540 patient cohort, and enrolled 3.25% of their patients on cancer treatment trials during the 5-year observation period (vs 0.27% enrollment among low engagement practices). Practices with low vs high research engagement treated higher proportions of the following patient groups: ages 75 years and older (24.2% vs 21.8%), non-Latinx Black (12.6% vs 10.3%) or Latinx (11.6% vs 6.1%), were within the lowest socioeconomic status quintile (21.9% vs16.5%), and were uninsured or had no documented insurance (22.2% vs 13.6%).

Conclusions: Patient groups historically underrepresented in oncology clinical trials are more likely to be treated at community practices with limited or no access to trials. These results suggest that investments to expand the clinical research footprint among practices with low research engagement could help address persistent inequities in trial representation.

Citing Articles

Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform.

Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y Contemp Clin Trials Commun. 2025; 44:101446.

PMID: 40027276 PMC: 11869879. DOI: 10.1016/j.conctc.2025.101446.


Structural racism and inequity in cancer clinical trial participation: time for solutions.

Pal A, Moussa R, Smith B, Brady B, Karikios D, Boyle F JNCI Cancer Spectr. 2024; 8(5).

PMID: 39438028 PMC: 11495864. DOI: 10.1093/jncics/pkae089.

References
1.
Caston N, Lalor F, Wall J, Sussell J, Patel S, Williams C . Ineligible, Unaware, or Uninterested? Associations Between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment. JCO Oncol Pract. 2022; 18(11):e1854-e1865. PMC: 9653198. DOI: 10.1200/OP.22.00359. View

2.
Unger J, Gralow J, Albain K, Ramsey S, Hershman D . Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. 2015; 2(1):137-9. PMC: 4824189. DOI: 10.1001/jamaoncol.2015.3924. View

3.
Williams P, Zaidi S, Sengupta R . AACR Cancer Disparities Progress Report 2022. Cancer Epidemiol Biomarkers Prev. 2022; 31(7):1249-1250. DOI: 10.1158/1055-9965.EPI-22-0542. View

4.
Virani S, Burke L, Remick S, Abraham J . Barriers to recruitment of rural patients in cancer clinical trials. J Oncol Pract. 2011; 7(3):172-7. PMC: 3092658. DOI: 10.1200/JOP.2010.000158. View

5.
Denicoff A, McCaskill-Stevens W, Grubbs S, Bruinooge S, Comis R, Devine P . The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract. 2013; 9(6):267-76. PMC: 3825288. DOI: 10.1200/JOP.2013.001119. View